Evidence map›Paper›PMID 42492143›Full record

ArticleJournal of the neurological sciences2026

Association between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity.

Huanwen Chen, Dhairya A Lakhani, Sridhara S Yaddanapudi, Shahrzad Latifikhereshky, Pranjal Rai, Jay Kakadiya, Ajay Malhotra, Marco Colasurdo, Dheeraj Gandhi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the neurological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huanwen ChenDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA; Department of Neurology, University of Maryland Medical Center, Baltimore, MD, USA.
Dhairya A LakhaniDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Sridhara S YaddanapudiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Shahrzad LatifikhereshkyDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Pranjal RaiDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Jay KakadiyaDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Ajay MalhotraDepartment of Radiology, Yale University, New Haven, CT, USA.
Marco ColasurdoDepartment of Interventional Radiology, Oregon Health and Science University, Portland, OR, USA.
Dheeraj GandhiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA. Electronic address: Dheeraj.gandhi@som.umaryland.edu.

Funding

West Virginia Clinical and Translational Science Institute: A Statewide Organization Building Research Excellence and Engaging Communities to Improve HealthU54GM104942 · WEST VIRGINIA UNIVERSITY · 2025 to 2025
$4.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce stroke incidence, but their impact on the severity of acute ischemic stroke (AIS) when events occur remains unclear. The aim of this study is to evaluate whether pre-stroke GLP-1RA use is associated with reduced ischemic stroke severity and improved post-stroke outcomes.

methodWe conducted a retrospective cohort study using the 2016-2024 data from the TriNetX US Collaborative Network. Patients were categorized based on documented use of GLP-1RAs for at least six months prior to the index stroke event. After, propensity score matching, primary outcome was measured by the National Institutes of Health Stroke Scale (NIHSS), with secondary outcomes including rates of severe stroke (NIHSS ≥10), intensive care unit admission, neurological symptoms, in-hospital complications, and 30-day mortality.

resultsA total of 209,180 first-time AIS patients were identified, of whom 4773 (2.3%) were GLP-1RA users. After PSM, 4769 patients remained in each group. GLP-1RA users had lower median NIHSS (3 vs 4, p < 0.001). GLP-1RA users also had lower rates of severe stroke (18.4% vs 25.5%, p < 0.001), dysphagia/dysarthria (43.5% vs 48.0%, p < 0.001), aphasia (25.2% vs 28.7%, p < 0.001), hemiplegia/hemiparesis (37.6% vs 43.3%, p < 0.001), intracranial hemorrhage (13.2% vs 14.7%, p = 0.031), and 30-day mortality (6.3% vs 7.6%, p = 0.016).

conclusionsAmong adult patients who suffered a first-time AIS, pre-stroke use of GLP-1RA was associated with reduced stroke severity, lower rates of symptoms and complications, and lower mortality. These findings suggest that the benefits GLP-1RA may extend beyond preventing the occurrence of cerebrovascular events.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsIschemic StrokeAgedAged, 80 and overBrain IschemiaFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexGlucagon-Like Peptide-1 Receptor AgonistsGLP-1RAIschemic strokeMortalityTriNetX

Identifiers

PMID42492143
PMCPMC13452011

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.